Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Ocular Therapeutix Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Ocular Therapeutix Inc, Medical Devices Deals, 2012 to YTD 2018 10
Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Ocular Therapeutix Raises US$8.5 Million In Series E Venture Financing 12
Ocular Therapeutix Raises US$24 Million In Extended Series D Financing 13
Partnerships 15
Regeneron Pharma Enters into Co-Development Agreement with Ocular Therapeutix 15
Equity Offering 17
Ocular Therapeutix Raises USD37.3 Million in Public Offering of Shares 17
Ocular Therapeutix Prices Public Offering of Shares for USD25 Million 19
Ocular Therapeutix Raises USD101.2 Million in Public Offering of Shares 21
Ocular Therapeutix Completes Exercise of Underwriter’s Over Allotment Option for IPO for USD75 Million 23
Ocular Therapeutix Inc – Key Competitors 25
Ocular Therapeutix Inc – Key Employees 26
Ocular Therapeutix Inc – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Financial Announcements 28
Aug 07, 2018: Ocular Therapeutix announces second quarter 2018 financial results 28
Mar 08, 2018: Ocular Therapeutix Reports Fourth Quarter and Year End 2017 Financial Results and Business Update 29
Nov 07, 2017: Ocular Therapeutix Reports Third Quarter 2017 Financial Results and Provides Corporate Update 31
Aug 08, 2017: Ocular Therapeutix Reports Second Quarter 2017 Financial Results and Provides Corporate Update 33
Aug 03, 2017: Ocular Therapeutix Appoints Daniel Bollag, Ph.D., as Senior Vice President, Regulatory Affairs, Pharmacovigilance and Quality 35
Aug 01, 2017: Ocular Therapeutix Announces Antony Mattessich Assumes Role as Chief Executive Officer 36
May 05, 2017: Ocular Therapeutix Reports First Quarter 2017 Financial Results 37
Corporate Communications 39
Sep 08, 2017: Ocular Therapeutix Appoints Michael Goldstein, M.D., M.B.A., as Chief Medical Officer 39
Jun 26, 2017: Ocular Therapeutix Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 40
Jun 22, 2017: Ocular Therapeutix Announces Executive Transition Plans 41
Apr 06, 2017: Ocular Therapeutix Appoints George Migausky as Interim Chief Financial Officer 42
Mar 10, 2017: Ocular Therapeutix Reports Fourth Quarter and Full Year 2016 Financial Results 43
Product News 45
12/22/2017: Ocular Therapeutix Provides Legal Update 45
05/02/2017: Ocular Therapeutix Announces Data on OTX-TKI at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 46
01/08/2018: Ocular Therapeutix Announces Kevin Hanley as Senior Vice President, Technical Operations and Naymisha Patel as Vice President of Quality 47
Product Approvals 48
Jul 12, 2017: OCULAR THERAPEUTIX INVESTOR ALERT: Legal Investigation Continues After FDA Denies Dextenza New Drug Application 48
Jul 11, 2017: Ocular Therapeutix Receives Complete Response Letter from FDA for DEXTENZA NDA 49
Jul 10, 2017: Ocular Therapeutix Submits Amendment to Potentially Extend Review for DEXTENZA New Drug Application 50
Feb 22, 2017: Ocular Therapeutix Announces FDA Acceptance of NDA Resubmission for DEXTENZA for the Treatment of Ocular Pain Occurring After Ophthalmic Surgery 51
Jan 23, 2017: Ocular Therapeutix Resubmits NDA for DEXTENZA for the Treatment of Ocular Pain Occurring After Ophthalmic Surgery 52
Clinical Trials 53
Apr 09, 2018: Ocular Therapeutix to Present Data at the American Society of Cataract and Refractive Surgery Symposium 53
May 11, 2017: Ocular Therapeutix Presented Phase 3 Data for DEXTENZA at the Association for Research in Vision and Ophthalmology Annual Meeting 54
May 09, 2017: Ocular Therapeutix Presents Preclinical Data on Pharmacokinetics, Efficacy and Tolerability of Sustained Release Intravitreal Tyrosine Kinase Inhibitor Hydrogel Depot (OTX-TKI) at the ARVO Annual Meeting 56
May 08, 2017: Ocular Therapeutix Presents Additional Phase 3 Data and Patient Reported Outcomes Results for DEXTENZA at the American Society of Cataract and Refractive Surgery (ASCRS) Symposium 58
May 02, 2017: Ocular Therapeutix to Present Data on DEXTENZA at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 59
May 02, 2017: Ocular Therapeutix to Present Data on OTX-TP (travoprost insert) at the Association for Research in Vision and Ophthalmology Annual Meeting 60
Apr 24, 2017: Ocular Therapeutix to Present Additional Phase 3 Data and Patient Reported Outcomes Results for DEXTENZA at the American Society of Cataract and Refractive Surgery (ASCRS) Symposium 61
Mar 15, 2017: New Publication Describes Positive Patient Experience in Study of Ocular Therapeutix DEXTENZA Following Cataract Surgery 63
Jan 04, 2017: Ocular Therapeutix Announces Additional Successful Results for Phase 3 Clinical Trial of DEXTENZA 64
Appendix 65
Methodology 65
About GlobalData 65
Contact Us 65
Disclaimer 65
Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Ocular Therapeutix Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Ocular Therapeutix Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Ocular Therapeutix Inc, Medical Devices Deals, 2012 to YTD 2018 10
Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Ocular Therapeutix Raises US$8.5 Million In Series E Venture Financing 12
Ocular Therapeutix Raises US$24 Million In Extended Series D Financing 13
Regeneron Pharma Enters into Co-Development Agreement with Ocular Therapeutix 15
Ocular Therapeutix Raises USD37.3 Million in Public Offering of Shares 17
Ocular Therapeutix Prices Public Offering of Shares for USD25 Million 19
Ocular Therapeutix Raises USD101.2 Million in Public Offering of Shares 21
Ocular Therapeutix Completes Exercise of Underwriter's Over Allotment Option for IPO for USD75 Million 23
Ocular Therapeutix Inc, Key Competitors 25
Ocular Therapeutix Inc, Key Employees 26
Ocular Therapeutix Inc, Other Locations 27
List of Figures
Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Ocular Therapeutix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Ocular Therapeutix Inc, Medical Devices Deals, 2012 to YTD 2018 10